An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Fibromyalgia

Trial Profile

An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Fibromyalgia

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Duloxetine (Primary)
  • Indications Fibromyalgia
  • Focus Adverse reactions; Registrational
  • Sponsors Eli Lilly; Shionogi
  • Most Recent Events

    • 20 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Apr 2013 Planned End Date changed from 1 Jan 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 21 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top